UFMylation of Pyruvate Dehydrogenase Regulates Mitochondrial Metabolism

This study reveals that UFMylation of the pyruvate dehydrogenase subunit DLAT at lysine 118 activates mitochondrial metabolism by enhancing pyruvate oxidation, a process normally regulated by the de-UFMylase UFSP2.

The Gist

The Big Picture: A Cellular Power Plant with a Stuck Throttle

Imagine your cells are like massive, bustling cities. Inside every cell, there is a power plant called the mitochondrion. Its job is to burn fuel (sugar/glucose) to create electricity (energy) that keeps the city running.

For a long time, scientists knew about a tiny "tag" called UFM1 that sticks to proteins. They thought this tag mostly worked in the city's "warehouse" (the Endoplasmic Reticulum) or the "city hall" (the nucleus). They didn't think it had anything to do with the power plant.

This paper discovers that the UFM1 tag actually has a huge job inside the power plant, and it works like a gas pedal for burning sugar.

---

The Characters in Our Story

1. The Fuel (Glucose): The sugar we eat.
2. The Engine (Pyruvate Dehydrogenase or PDH): A massive machine inside the power plant. Its job is to take the fuel (glucose) and convert it into a form the engine can burn.
3. The Tag (UFM1): A sticky note that can be attached to the engine.
4. The Mechanic (UFSP2): A specialized worker whose job is to peel off the sticky notes.
5. The Stuck Throttle: What happens when the mechanic is missing.

The Discovery: What Happens When the Mechanic is Missing?

The researchers studied cells where the Mechanic (UFSP2) was removed.

• The Problem: Without the mechanic to peel off the sticky notes, the UFM1 tags started piling up everywhere.
• The Surprise: They found these sticky notes piling up on the Engine (PDH), specifically on a part called DLAT.
• The Result: The engine didn't just run normally; it went into overdrive.
  • The cells started burning sugar much faster.
  • They produced energy much faster.
  • It was as if someone had taped the gas pedal to the floor.

The Analogy: Imagine a car with a mechanic who usually removes a "speed limit" sticker from the dashboard. If you fire the mechanic, the sticker stays on, but in this case, the sticker actually removes the speed limit! The car (the cell) revs its engine way too high.

The Specific Mechanism: The "Swinging Arm"

The researchers zoomed in on the Engine (PDH) to see exactly where the sticky note (UFM1) was attached.

• The Engine has a part called DLAT that acts like a swinging arm. It grabs fuel, swings it over, and drops it into the fire to make energy.
• The sticky note (UFM1) attached itself to a specific spot on this arm (a spot called K118).
• What did the note do? It didn't break the arm; it made the arm swing faster and more efficiently.
• The Proof: When the researchers mutated the arm so the sticky note couldn't attach (by changing a specific letter in the DNA code), the engine slowed down. The "overdrive" effect disappeared.

Why Does This Matter?

This is a big deal for two reasons:

1. Understanding Disease: There are people born with mutations in the Mechanic (UFSP2). They suffer from severe developmental issues, bone problems, and sometimes neurological disorders.
   • The Theory: Because their "mechanic" is broken, their cells' power plants are constantly revving too high. This creates too much heat and waste (oxidative stress), which damages the cells, especially in the brain and bones. It's like a car engine running so hot it melts its own pistons.
2. New Metabolic Rules: Scientists thought the "gas pedal" for burning sugar was controlled by other things (like turning the engine on or off). This paper shows that sticking a UFM1 note on the engine is a brand new way to control how fast we burn fuel.

Summary in One Sentence

This paper reveals that a tiny cellular tag (UFM1) acts as a gas pedal for our cell's energy engine, and a specific worker (UFSP2) is needed to take that tag off; without the worker, the engine runs too fast, which might explain why certain genetic diseases cause severe health problems.

Technical Summary

1. Problem Statement

The ubiquitin-fold modifier 1 (UFM1) post-translational modification (UFMylation) is essential for human development and protein homeostasis. While the enzymatic cascade for UFMylation (E1: UBA5, E2: UFC1, E3: UFL1) and its removal by de-UFMylases (UFSP1 and UFSP2) are known, the specific physiological roles of UFSP2 remain poorly characterized.

• Clinical Context: Pathogenic variants in UFSP2 are linked to severe human disorders, including skeletal dysplasias (e.g., SEMDDR) and neurodevelopmental/epileptic encephalopathies.
• Knowledge Gap: Although UFSP2 is known to deconjugate UFM1 from ribosomal proteins (RPL26) in the context of ER stress and ribosome quality control, its role in mitochondrial metabolism and the identity of mitochondrial UFMylated substrates were previously unknown.

2. Methodology

The authors employed a multi-omics and functional genomics approach to investigate the impact of UFSP2 deficiency on cellular metabolism:

• Proteomics (IP-MS):
  • Generated UFSP2-knockout (∆UFSP2) 293T cells stably expressing Flag-tagged wild-type UFM1 (UFM1WT) or a conjugation-deficient mutant (UFM1DGSC).
  • Overexpressed the UFMylation machinery (UBA5, UFC1, UFL1, DDRGK1) to maximize UFMylated protein detection.
  • Performed immunoprecipitation (IP) followed by mass spectrometry (MS) to identify UFMylated proteins accumulating in the absence of UFSP2.
• Cell Line Engineering:
  • Created isogenic knockout cell lines (HeLa, HCT116, PANC-1) for UFM1 (∆UFM1) and UFSP2 (∆UFSP2).
  • Generated rescue lines in ∆UFSP2 cells expressing: Empty Vector (EV), Wild-type UFSP2 (WT), or a catalytically dead mutant (C302S).
  • Generated DLAT (PDH E2 subunit) knockout cells and reconstituted them with WT or lysine-mutated DLAT (K118R, K363R, K547R).
• Metabolic Phenotyping:
  • Seahorse XF Respirometry: Measured Oxygen Consumption Rates (OCR) to assess basal and maximal mitochondrial respiration.
  • Stable Isotope Tracing: Used [U-13C]glucose and [U-13C]glutamine to track carbon flux through glycolysis, the TCA cycle, and acetyl-CoA production.
  • Acetyl-CoA Measurement: Quantified isotopologue enrichment (m+2) of acetyl-CoA derived from glucose.
• Biochemical Validation:
  • Immunoblotting: Assessed global UFMylation, protein abundance, phosphorylation (PDHA1), and lipoylation (DLAT) status.
  • PDH Activity Assay: Measured enzymatic activity of the Pyruvate Dehydrogenase complex directly.
  • LC-MS/MS: Identified specific lysine residues on DLAT modified by UFM1.
  • Blue Native PAGE: Analyzed the assembly of Electron Transport Chain (ETC) supercomplexes.

3. Key Contributions

• Discovery of Mitochondrial UFMylation: The study identifies the mitochondria as a major site of UFMylation, revealing that UFSP2 deficiency leads to the hyper-accumulation of UFM1 on mitochondrial ribosomal proteins, ETC complexes, and the Pyruvate Dehydrogenase (PDH) complex.
• Identification of DLAT as a Direct Substrate: The authors identified Dihydrolipoamide S-acetyltransferase (DLAT), the E2 subunit of the PDH complex, as a direct UFMylation substrate.
• Mapping the Modification Site: They pinpointed Lysine 118 (K118) on DLAT as the primary site of UFMylation.
• Mechanistic Insight: They demonstrated that UFMylation at K118 acts as a gain-of-function modification that activates PDH enzymatic activity, distinct from the canonical inhibitory phosphorylation of the PDH complex.

4. Key Results

• UFSP2 Deficiency Increases Mitochondrial Respiration:
  • ∆UFSP2 cells exhibited significantly higher basal and maximal oxygen consumption rates (OCR) compared to controls or ∆UFM1 cells.
  • This increase was not due to changes in mitochondrial protein abundance, membrane potential, mtDNA copy number, or ETC supercomplex assembly, suggesting enhanced substrate flux.
• Enhanced Glucose Oxidation via PDH:
  • Isotope tracing with [U-13C]glucose showed that ∆UFSP2 cells had elevated fractional enrichment of citrate m+2 and downstream TCA intermediates, indicating increased flux from pyruvate to acetyl-CoA.
  • The ratio of citrate m+2 to pyruvate m+3 was higher in ∆UFSP2 cells, specifically implicating the PDH step.
  • Supplementation with acetate (which bypasses PDH to generate acetyl-CoA via ACSS1) normalized the respiratory phenotype, confirming the defect is specific to the PDH-mediated pyruvate oxidation step.
• DLAT UFMylation Drives PDH Activity:
  • Immunoprecipitation confirmed DLAT is UFMylated in ∆UFSP2 cells.
  • K118 is the critical site: Mutating K118 to Arginine (K118R) abolished DLAT UFMylation.
  • Functional Consequence: Re-expression of K118R DLAT in ∆UFSP2/∆DLAT cells reduced both basal respiration and maximal respiratory capacity back to control levels.
  • Enzymatic Activity: PDH activity assays confirmed that cells lacking UFSP2 (or expressing WT DLAT) have higher PDH enzymatic activity than those expressing K118R DLAT.
  • Mechanism: The K118 site is adjacent to the lipoylation site (K132). The authors propose that UFM1 conjugation induces steric or electrostatic shifts that enhance the conformational flexibility of the "swinging arm" lipoyl domain, accelerating acetyl group transfer.

5. Significance

• Novel Regulatory Layer: This study establishes UFMylation as a direct, positive regulator of mitochondrial metabolism, specifically controlling the entry of glucose-derived carbon into the TCA cycle via PDH activation.
• Pathophysiological Insight: It provides a biochemical mechanism for UFSP2-related human diseases. The accumulation of UFM1 on DLAT (K118) in patients with UFSP2 mutations leads to unregulated mitochondrial hyperactivity.
• Disease Implications:
  • Neurodegeneration: In post-mitotic cells like neurons, chronic PDH hyperactivity could lead to excessive Reactive Oxygen Species (ROS) production, mitochondrial damage, and synaptic loss, potentially explaining the neurodegenerative phenotypes seen in UFSP2 patients and Alzheimer's disease.
  • Cancer: Given the role of PDH in metabolic reprogramming, dysregulated UFMylation may contribute to the metabolic flexibility observed in various cancers.
• Therapeutic Potential: The identification of the UFSP2-PDH axis suggests that modulating UFMylation or targeting the specific K118 site could be a strategy to correct metabolic imbalances in metabolic disorders and neurodegenerative diseases.